OCTA and Polypoidal Choroidal Vasculopathy

Study Overview
=================
Brief Summary
-----------------
To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.

Detailed Description
-----------------
Polypoidal choroidal vasculopathy represents a distinct form of choroidal neovascularization. The study investigated the changes in choroidal vascular network after anti-VEGF therapy using optical coherence tomography angiography, a novel and non invasive diagnostic technique that allows to better understand the pathophysiologic mechanism of this neovascularization.

Official Title
-----------------
Choroid and Choriocapillary Changes in Polypoidal Choroidal Vasculopathy After Intravitreal Anti-VEGF Therapy

Conditions
-----------------
Polypoidal Choroidal Vasculopathy

Intervention / Treatment
-----------------
* Drug: Ranibizumab Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age older than 60 years diagnosis of polypoidal choroidal vasculopathy absence of previous ocular surgery, congenital eye disease, high myopia (>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases. absence of significant lens opacities, low-quality OCT-A images. Exclusion Criteria: age older than 80 years absence of diagnosis of polypoidal choroidal vasculopathy presence of previous ocular surgery, congenital eye disease, high myopia (>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases. presence of significant lens opacities, low-quality OCT-A images.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients underwent anti-VEGF therapy<br>intravitreal Anti-VEGF therapy: Three monthly intravitreal injections | Drug: Ranibizumab Injection<br>* Three monthly intravitreal injections of Ranibizumab<br>* Other names: Lucentis;|
| Control Group<br>Healthy eyes without actual and previous ocular diseases | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of vascular features of choroid in polypoidal choroidal vasculopathy after intravitreal injections of Ranibizumab | The effectiveness of Ranibizumab injections for treating PCV using optical optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: choriocapillaris vessel density. | 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of structural features of choroid in polypoidal choroidal vasculopathy after intravitreal | The effectiveness of Ranibizumab injections for treating PCV using optical optical coherence tomography. The parameters analyzed by optical coherence tomography were: subfoveal choroidal thickness. | 12 Months |